ASX / Media Release
20 May 2022

Upcoming Presentations to the 92nd Aerospace Medical Association Annual Scientific Meeting

Invex Therapeutics Ltd (**Invex**, **ASX:IXC,** or **the Company**) a clinical-stage biopharmaceutical company focused on the development and commercialisation of Presendin™ (sustained release Exenatide) for neurological conditions relating to raised intracranial pressure, today announces several upcoming oral presentations at the 92nd Aerospace Medical Association Annual Scientific Meeting from 22-27 May 2022 in Reno, Nevada.

Dr James L. Mitchell of the Institute of Metabolism and Systems Research, University of Birmingham, UK on behalf of Invex's Phase II Pressure Trial in Idiopathic Intracranial Hypertension (IIH) will present key findings of this clinical trial with an oral presentation titled *"A randomized controlled, Trial of the GLP-1 Receptor Agonist Exenatide in Idiopathic Intracranial Hypertension."*

Professor Alex Sinclair, Invex Executive Director and Chief Scientific Officer and Clinician Scientist and Neurology Consultant in the Metabolic Neurology Group at the Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, The University of Birmingham will present data on monitoring intracranial pressure in IIH using telemetric monitoring from the Phase II Pressure Trial. In addition, Dr Sinclair will co-chair a scientific panel titled *"Understanding and Modifying Intracranial Pressure and Spaceflight."*

Professor Sinclair commented "Continued data presentation and disclosure of our successful Phase II Pressure Trial to our scientific and medical peers is an essential part of the peer-review process, while also harnessing clinician participation in our upcoming IIH EVOLVE Phase III clinical trial, where interest to date has been exceptionally strong and the need for new drugs like Presendin™ to treat IIH patients more urgent than ever. In addition, my presentation to aerospace medical colleagues is designed to highlight the effects of space travel on intracranial pressure and the IIH-like effects this has on astronauts, which we now designate as space flight-associated neuro-ocular syndrome or SANS, and how GLP-1 agonists such as Presendin™ may be beneficial in alleviating these symptoms."

The Aerospace Medical Association is organized exclusively for charitable, educational, and scientific purposes. It is the largest, most-representative professional membership organization in the fields of aerospace medicine and human performance. Aerospace medicine concerns the determination and maintenance of the health, safety, and performance of persons involved in air and space travel.

For more information on the 92nd Annual Scientific Meeting, please click here.

For more information on the association of space travel and intracranial pressure and the use of GLP-1 agonists, please click here.

- ENDS -

This release dated 20 May 2022 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics.

For more information, please contact:

Company/Investors
Dr Thomas Duthy
Executive Director
tduthy@invextherapeutics.com
+61 402 493 727

Media
Margie Livingston
Ignite Communications
margie@ignitecommunications.com.au
+61 438 661 131

To subscribe to Invex email alerts, please visit www.invextherapeutics.com and follow us on Twitter **@InvexThera_ASX**

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.

About Idiopathic Intracranial Hypertension (IIH)

IIH features severely raised intracranial pressure which causes disabling daily headaches and can compress the optic nerve. The usual age of onset is 20-30 years, and it is most common in women who are obese. IIH is a rapidly growing orphan indication: its incidence has increased by more than 350% in the last 10 years.

About Presendin™

Presendin™ is a once per week, sub-cutaneous, sustained-release (SR) Exenatide microsphere formulation originally developed by Peptron, Inc. (KOSDAQ: 087010). In September 2021 Invex entered into an exclusive collaboration, manufacturing and supply agreement with Peptron for Presendin™ in IIH for all major markets, with the exception of South Korea.

Exenatide is a small peptide and a synthetic version of the GLP-1 agonist exendin-4, which is currently approved for the treatment of type 2 diabetes. In 2017, Invex received orphan drug

designation for Exenatide in IIH from the US Food and Drug Administration and European Medicines Agency.